Atossa Therapeutics Files Q2 2024 10-Q
Ticker: ATOS · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 10-Q |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.18 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech, R&D
TL;DR
ATOS Q2 10-Q filed. Financials updated, R&D spending and share buybacks noted.
AI Summary
Atossa Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position, including common stock, additional paid-in capital, and Series B Convertible Preferred Stock. Key activities during the reporting period included share repurchases and research and development expenses.
Why It Matters
This filing provides investors with an update on Atossa Therapeutics' financial health and operational activities for the second quarter of 2024, including R&D spending and share buybacks.
Risk Assessment
Risk Level: medium — Biotech companies like Atossa Therapeutics often face inherent risks related to drug development, clinical trials, and regulatory approvals.
Key Numbers
- 2024-06-30 — Reporting Period End (Financials as of this date)
- 2024-08-12 — Filing Date (Date the report was submitted)
- 2024-01-01 to 2024-06-30 — Share Repurchase Program (Period during which repurchases occurred)
- 2024-04-01 to 2024-06-30 — R&D Expense Period (Second quarter R&D spending)
Key Players & Entities
- ATOSSA THERAPEUTICS, INC. (company) — Filer
- 2024-06-30 (date) — Reporting Period End Date
- 2024-08-12 (date) — Filing Date
- SEATTLE, WA (location) — Company Headquarters
- 2023-03-31 (date) — Comparative Financial Date
- 2024-01-01 2024-06-30 (date) — Share Repurchase Program Period
- 2023-04-01 2023-06-30 (date) — Comparative R&D Expense Period
- 2023-12-31 (date) — Prior Year End Financial Date
FAQ
What was the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing was the quarter ended June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 12, 2024.
What is Atossa Therapeutics, Inc.'s primary business classification?
Atossa Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834].
Did Atossa Therapeutics engage in share repurchases during the reporting period?
Yes, the filing indicates a Share Repurchase Program was active from January 1, 2024, to June 30, 2024.
What specific types of preferred stock are mentioned in the filing?
The filing mentions Series B Convertible Preferred Stock and Convertible Preferred Stock.
Filing Stats: 4,493 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2024-08-12 09:05:20
Key Financial Figures
- $0.18 — nge on which registered Common Stock, $0.18 par value ATOS The Nasdaq Capital M
Filing Documents
- atos-20240630.htm (10-Q) — 1412KB
- atos-ex10_2.htm (EX-10.2) — 99KB
- atos-ex31_1.htm (EX-31.1) — 13KB
- atos-ex31_2.htm (EX-31.2) — 13KB
- atos-ex32_1.htm (EX-32.1) — 8KB
- atos-ex32_2.htm (EX-32.2) — 8KB
- img96392089_0.jpg (GRAPHIC) — 105KB
- 0000950170-24-095102.txt ( ) — 6001KB
- atos-20240630.xsd (EX-101.SCH) — 1024KB
- atos-20240630_htm.xml (XML) — 708KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.
Controls and Procedures
Controls and Procedures 24 PART II. OTHER INFORMATION 25 Item 1.
Legal Proceedings
Legal Proceedings 25 Item 1A.
Risk Factors
Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45
—FINA NCIAL INFORMATION
PART I—FINA NCIAL INFORMATION
CONDENSED CONSOLIDATED FINAN CIAL STATEMENTS - UNAUDITED
ITEM 1. CONDENSED CONSOLIDATED FINAN CIAL STATEMENTS - UNAUDITED ATOSSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED B ALANCE SHEETS (amounts in thousands, except share and per share data) (Unaudited) June 30, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents $ 79,526 $ 88,460 Restricted cash 110 110 Prepaid materials 1,095 1,487 Prepaid expenses and other current assets 987 2,162 Total current assets 81,718 92,219 Investment in equity securities 1,710 1,710 Other assets 2,430 2,323 Total assets $ 85,858 $ 96,252 Liabilities and stockholders' equity Current liabilities Accounts payable $ 1,056 $ 806 Accrued expenses 1,907 973 Payroll liabilities 939 1,654 Other current liabilities 1,794 1,803 Total current liabilities 5,696 5,236 Total liabilities 5,696 5,236 Commitments and contingencies (Note 13) Stockholders' equity Convertible preferred stock - $ 0.001 par value; 10,000,000 shares authorized; 582 shares issued and outstanding as of June 30, 2024 and December 31, 2023 — — Common stock - $ 0.18 par value; 350,000,000 and 175,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively; 125,757,416 and 125,304,064 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 22,874 22,792 Additional paid-in capital 256,978 255,987 Treasury stock, at cost; 1,320,046 shares of common stock at June 30, 2024 and December 31, 2023 ( 1,475 ) ( 1,475 ) Accumulated deficit ( 198,215 ) ( 186,288 ) Total stockholders' equity 80,162 91,016 Total liabilities and stockholders' equity $ 85,858 $ 96,252 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 3 ATOSSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STAT EMENTS OF OPERATIONS (amounts in thousands, except share and per share data) (Un